BRIEF-Selecta Biosciences And Ginkgo Bioworks Holdings Inc Announce Partnership To Advance Treatments For Orphan And Rare Diseases
BRIEF-Selecta Biosciences And Ginkgo Bioworks Holdings Inc Announce Partnership To Advance Treatments For Orphan And Rare Diseases
Oct 26 (Reuters) - Ginkgo Bioworks Holdings Inc DNA.N :
路透10月26日电-银杏生物工程控股公司(Ginkgo Bioworks Holdings Inc DNA.N)：
* SELECTA BIOSCIENCES AND GINKGO BIOWORKS ANNOUNCE PARTNERSHIP TO ADVANCE TREATMENTS FOR ORPHAN AND RARE DISEASES
*Selecta Biosciences和Ginkgo Bioworks宣布建立合作伙伴关系，推进孤儿和罕见疾病的治疗
* SELECTA BIOSCIENCES - LEVERAGING GINKGO'S CELL PROGRAMMING PLATFORM & CO'S IMMTOR PLATFORM TO CREATE POTENTIALLY TRANSFORMATIVE ENZYMATIC THERAPIES
*Selecta Biosciences-利用银杏的细胞编程平台和CO的IMMTOR平台创建潜在的变革性酶疗法
* SELECTA BIOSCIENCES - GAINS RIGHTS TO DEVELOP, COMMERCIALIZE SELECT THERAPEUTIC ENZYMES FROM GINKGO'S ADVANCED ORGANISM ENGINEERING PLATFORM
*Selecta Biosciences-获得开发银杏先进生物工程平台的精选治疗酶的权利，并将其商业化
* SELECTA BIOSCIENCES - GINKGO IS ELIGIBLE TO EARN CLINICAL AND COMMERCIAL MILESTONE PAYMENTS OF UP TO $85M IN CASH
*Selecta Biosciences-银杏有资格获得高达8500万美元现金的临床和商业里程碑付款
* SELECTA BIOSCIENCES - GINKGO ELIGIBLE TO EARN UPFRONT RESEARCH & DEVELOPMENT FEES, MILESTONES, INCLUDING CERTAIN PAYMENTS IN FORM OF CO'S COMMON STOCK
*Selecta Biosciences-银杏有资格赚取预付研发费用、里程碑，包括以CO普通股形式支付的某些款项
Source text for Eikon: ID:nGNX7rtyW1 Further company coverage: DNA.N
Eikon的源文本：ID：nGNX7rtyW1进一步的公司报道：DNA.N